Revatio Pfizer Inc. - Treatment for Pulmonary Arterial HypertensionRevatio contains sildenafil citrate, the active ingredient in the erectile dysfunction medication Viagra. Revatio is indicated for the treatment of pulmonary arterial hypertension (PAH), a rare, aggressive and life-shortening vascular disease.
Posted: June 2005
- FDA Approves Intravenous Formulation Of Pfizer's Revatio (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension - November 20, 2009
- Pfizer Submits Regulatory Filings for Revatio as a Treatment for Pulmonary Arterial Hypertension - December 3, 2004
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.